PO246 Measuring treatment satisfaction in rms: teri-pro results

    loading  Checking for direct PDF access through Ovid



We examined the Treatment Satisfaction Questionnaire for Medication (TSQM), a generic 14-item, 4-domain (Effectiveness, Side Effects, Convenience, Global Satisfaction) scale using ‘real-world’ data from people with relapsing forms of MS (RMS).


Teri-PRO (NCT01895335) included teriflunomide-treated RMS patients (n=1000). A traditional psychometric evaluation examined: data completeness (item-level missing data); scaling assumptions (item means, variances, item-total correlations corrected for overlap, exploratory factor analysis [EFA]); scale-to-sample targeting (score distributions, floor/ceiling effects); internal consistency (Cronbach’s α, homogeneity coefficients); and aspects of construct validity.


Item-level missing data were low (<1%). Scaling assumptions were satisfied (similar item means/variances; item-domain correlations 0.63–0.90; EFA supported item groupings). Scale-to-sample targeting was adequate for scale evaluation; however, domain mean scores (66.3–90.3) notably exceeded scale midpoints (50), and ceiling effects for Convenience and Side Effects were high (57%, 58%). Internal consistency reliability was high (Cronbach’s α ≥0.86, homogeneity coefficients≥0.67). Standard errors of measurement were 5.49–7.02. Between-domain correlations (0.17–0.69) supported construct validity.


TSQM performance in Teri-PRO mirrors that in TENERE (NCT00883337) and supports the TSQM as a useful measure for RMS. However, high ceiling effects underestimate differences in treatment satisfaction. Better instruments, developed using more sophisticated methods, are needed.


Study supported by Sanofi Genzyme.

Related Topics

    loading  Loading Related Articles